The mutation Ala677 → Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis

Thrombosis and Haemostasis

Volumn 77, Issue 5, 1997, Pages 818-821

  Arruda, Valder R ^a   Von Zuben, Paula M ^a   Chiaparini, Luiz C ^a   Annichino Bizzacchi, Joyce M ^a   Costa, Fernando F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; BLOOD CLOTTING FACTOR 5; HOMOCYSTEINE; VALINE; BIOLOGICAL MARKER; CHOLESTEROL; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ALLELE; AMINO ACID BLOOD LEVEL; ANTITHROMBIN III DEFICIENCY; ARTERY DISEASE; ARTICLE; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CONTROLLED STUDY; DIABETES MELLITUS; DYSFIBRINOGENEMIA; FEMALE; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; HYPERLIPOPROTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS; BLOOD; CROSS-SECTIONAL STUDY; ENZYMOLOGY; GENETICS; GENOTYPE; HOMOZYGOTE; MIDDLE AGED; NEWBORN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POINT MUTATION; THROMBOPHLEBITIS;

ADOLESCENT; ADULT; ALANINE; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HOMOCYSTEINE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIAS; INFANT, NEWBORN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; RISK FACTORS; THROMBOPHLEBITIS; TRIGLYCERIDES; VALINE;

EID: 0030610090     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656059     Document Type: Article

References (36)

1. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114: 473-501.
2. Kang SS, Wong PWK, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-98.
3. Brattström L, Lindgren A. Hyperhomocysteinemia as a risk factor for stroke. Neurol Res 1992; 14: 81-4.
4. Verhoef P, Hennekens CH, Malinow R, Kok FJ, Willet WC, Stampfer MJ. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 1994; 25: 1924-30.
5. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-15.
6. Boushey CJ, Beresford SSA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
7. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
8. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-3.
9. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-5.
10. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
11. 6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57: 47-53.
12. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988; 81: 466-74.
13. Kraus JP. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis 1994; 17: 383-90.
14. Daly L, Robinson K, Tan KS, Graham I. Hyperhomocysteinemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences? Q J Med 1993; 86: 685-89.
15. Mudd SH, Havlik Rb, Levy HL, McKusick VA, Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet 1981; 33: 883-93.
16. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-50.
17. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052-9.
18. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-45.
19. Kang SS, Wong PWK, Zhou J, Sora J, Lessick M, Ruggie N, Grcevich G. Thermolabile methylenetetrahydrofolate reductase in patients with coronay artery disease. Metabolism 1988; 37: 611-3.
20. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
21. Franken DG, Boers GHJ, Blom HJ, Trijbels JMF, Kloppernborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994; 14: 465-70.
22. Froost P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GHJ, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahidrofolate reductase. Nature Genetics 1995; 10: 111-3.
23. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen Rl. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Human Genet 1996; 58: 35-41.
24. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996; 58: 17-20.
25. Ubbink JB, Vermaak WJH, Delport R, van der Merwe A, Becker PJ, Potgieter H. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr 1995; 62: 802-8.
26. Stein EA. Lipids, Lipoproteins, and Apolipoprotrein. In: Tieftz NW, editor. Fundamentals of Clinical Chemistry. Philadelphia, PA: W. B. Saunders, 1987: 449-81.
27. Lupus Anticoagulant Working Party. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44: 885-9.
28. Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reitsma FF. Factor V Leiden (FVQ506) is common in Brazilian population. Am J Hematol 1995; 39: 242-3.
29. Wolf M, Boyer-Neumann C, Martinoli J-L et al. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 1989; 62: 1144-5.
30. Odegaard OR, Try K, Abilgaard U. Protein C: a simplified semi-automated activity assay. Thromb Res 1986; 42: 257-62.
31. Abildgaard U, Lie M, Oldergaard OR. Antithrombin (heparin cofactor) assay with new chromogenic substrates. Thromb Res 1977; 11: 549-53.
32. Bowie EJW, Owen J CA. Clinical and laboratory diagnosis of hemorrhagic disorders. In: Ratnoff OD, Forbes CD, editors. Disorders of Hemostasis. Philadelphia: W. B. Saunders Company 1991: 48-74.
33. Millar SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from nucleated cell. Nucleic Acids Res 1988; 16: 1215.
34. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-91.
35. Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH, Dicker RC, Sullivan KM, Fagan RF, Arner TG. Epi Info, version 6: a word processing, database, and statistics program for epidemiology on microcomputers. Atlanta: Center for Disease Control and Prevention, 1994.
36. Wilcken DEL, Wang XL, Sim AS, McCredie. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vase Biol 1996; 16: 878-82.